New Zealand Approves Psychiatrists to Prescribe MDMA for PTSD Treatment
Associate Health Minister David Seymour welcomes Medsafe’s approval for two psychiatrists to prescribe pharmaceutical grade MDMA for treating PTSD through psychedelic-assisted therapy, aligning New Zealand with Australia’s clinical practices. MDMA remains unapproved as a medicine, but strict safeguards and comprehensive clinical assessments ensure its safe and appropriate use within a controlled therapeutic setting, with no take-home dispensing allowed. This approval is specific to the two psychiatrists, requiring other clinicians to obtain separate Medsafe authorization, reflecting a commitment to expanding access to innovative treatments responsibly.